Role of PD-1/PD-L1 pathway in the development of Head and neck squamous cell carcinoma (HNSCC)
The human immune system has the innate capability to recognize and eliminate cancer cells. However,…
Resources
Key differences between HPV-positive and HPV-negative head and neck squamous cell carcinomas (HNSCC)
Head and neck squamous cell carcinomas (HNSCC) develop from the mucosal epithelium in the oral…
Sysmex Inostics & QIAGEN Highlight Cancer Companion Diagnostics Alliance at ASCO 2022
Two poster presentations utilizing Sysmex Inostics technology to be featured Baltimore, MD, June 2, 2022…
Sysmex Inostics Expands Blood Test Offerings for Detection of Acute Myeloid Leukemia
Joins Foundation for the National Institutes of Health Biomarkers Consortium Baltimore, MD, May 24, 2022…
Sysmex Inostics Introduces CLIA-Validated Highly Sensitive HNSCC-SEQ Testing Services for Head and Neck Cancer at the 2022 Molecular Medicine Tri-Conference
Presenting Poster of Clinical Trial Findings at 2022 Multidisciplinary Head and Neck Cancers Symposium Baltimore,…
University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD, January 26, 2022 – Sysmex Inostics, a global leader in the liquid biopsy…
New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics
Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal…
Sysmex Forms Strategic Alliance with QIAGEN to Provide Global Cancer Companion Diagnostics that Uses Ultra-sensitive Liquid Biopsy NGS Technology
Sysmex Inostics is working to strengthen its global relationship with pharmaceutical companies in order to…
Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated Plasma-Safe-SeqS cfHPV-DNA assay, is highly effective for measuring HPV DNA in the plasma of patients with OPSCC enrolled in the OPTIMA 2 treatment de-escalation trial.
Baltimore, MD, 2021.06.02 – Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution…
Sysmex Inostics Presents Data Demonstrating Exquisite Sensitivity of Plasma-Safe-SeqS NGS Detection of MRD AML at ASH Annual Meeting
Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity…
Sysmex Inostics’ Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Baltimore, MD, 2020.09.08 – Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating…
Sysmex Inostics’ OncoBEAM™ RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, Maryland, 2020.08.27 – Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor…